FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366332806> ?p ?o ?g. }

• W4366332806 endingPage "e064675" @default.
• W4366332806 startingPage "e064675" @default.
• W4366332806 abstract "Objective To evaluate the feasibility of conducting a large clinical trial within the Rwandan mental healthcare system that would establish the safety, efficacy and benefit of paliperidone palmitate once-monthly (PP1M) and once-every-3-months (PP3M) long-acting injectable formulations in adults with schizophrenia. Study design An open-label, prospective feasibility study. Setting/Participants 33 adult patients with schizophrenia were enrolled at 3 sites across Rwanda. Interventions The study design included 3 phases of treatment: an oral run-in to establish tolerability to risperidone (1 week), lead-in treatment with flexibly dosed PP1M to identify a stable dose (17 weeks) and maintenance treatment with PP3M (24 weeks). Primary and secondary outcome measures Feasibility endpoints included compliance with governmental and institutional requirements, acceptable supply chain delivery and proper onsite administration of risperidone/PP1M/PP3M, adequate site infrastructure, adequate training of clinical staff and successful completion of study procedures and scales. A variety of study scales were administered to assess outcomes relevant to patients, caregivers, clinicians and payers in Rwanda and other resource-limited settings. Results This study was terminated early by the sponsor because certain aspects of study conduct needed to be addressed to maintain Good Clinical Practice requirements and meet regulatory standards. Results identified areas for improvement in study execution, including study governance, site infrastructure, study preparation and conduct of procedures, study budget and study assessments. Despite the identification of areas in need of adjustment, none of these limitations were considered insurmountable. Conclusions This work was designed to strengthen global research in schizophrenia by building the capacity of researchers to prepare and conduct pharmaceutical trials in resource-limited settings. Although the study was ended early, modifications motivated by the results will facilitate the successful design and completion of more comprehensive studies, including an ongoing, follow-up interventional trial of PP1M/PP3M in a larger population of patients in Rwanda. Trial registration number NCT03713658" @default.
• W4366332806 created "2023-04-20" @default.
• W4366332806 creator A5001380819 @default.
• W4366332806 creator A5003058961 @default.
• W4366332806 creator A5007031068 @default.
• W4366332806 creator A5007836898 @default.
• W4366332806 creator A5014423400 @default.
• W4366332806 creator A5050361217 @default.
• W4366332806 creator A5052807968 @default.
• W4366332806 creator A5055392951 @default.
• W4366332806 creator A5071518287 @default.
• W4366332806 creator A5072940042 @default.
• W4366332806 creator A5091786784 @default.
• W4366332806 date "2023-04-01" @default.
• W4366332806 modified "2023-09-25" @default.
• W4366332806 title "Feasibility study to evaluate capabilities for conducting psychiatric clinical research within the Rwandan mental healthcare system" @default.
• W4366332806 cites W1440308671 @default.
• W4366332806 cites W2036063318 @default.
• W4366332806 cites W2052968398 @default.
• W4366332806 cites W2055465804 @default.
• W4366332806 cites W2084779737 @default.
• W4366332806 cites W2104175708 @default.
• W4366332806 cites W2109935313 @default.
• W4366332806 cites W2140000974 @default.
• W4366332806 cites W2290987402 @default.
• W4366332806 cites W2618194374 @default.
• W4366332806 cites W2621159104 @default.
• W4366332806 cites W2793825585 @default.
• W4366332806 cites W2885976838 @default.
• W4366332806 cites W2887473284 @default.
• W4366332806 cites W2955902202 @default.
• W4366332806 cites W3090172502 @default.
• W4366332806 cites W3171418018 @default.
• W4366332806 cites W4254230094 @default.
• W4366332806 doi "https://doi.org/10.1136/bmjopen-2022-064675" @default.
• W4366332806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37072361" @default.
• W4366332806 hasPublicationYear "2023" @default.
• W4366332806 type Work @default.
• W4366332806 citedByCount "0" @default.
• W4366332806 crossrefType "journal-article" @default.
• W4366332806 hasAuthorship W4366332806A5001380819 @default.
• W4366332806 hasAuthorship W4366332806A5003058961 @default.
• W4366332806 hasAuthorship W4366332806A5007031068 @default.
• W4366332806 hasAuthorship W4366332806A5007836898 @default.
• W4366332806 hasAuthorship W4366332806A5014423400 @default.
• W4366332806 hasAuthorship W4366332806A5050361217 @default.
• W4366332806 hasAuthorship W4366332806A5052807968 @default.
• W4366332806 hasAuthorship W4366332806A5055392951 @default.
• W4366332806 hasAuthorship W4366332806A5071518287 @default.
• W4366332806 hasAuthorship W4366332806A5072940042 @default.
• W4366332806 hasAuthorship W4366332806A5091786784 @default.
• W4366332806 hasBestOaLocation W43663328061 @default.
• W4366332806 hasConcept C118552586 @default.
• W4366332806 hasConcept C134362201 @default.
• W4366332806 hasConcept C142724271 @default.
• W4366332806 hasConcept C160735492 @default.
• W4366332806 hasConcept C162324750 @default.
• W4366332806 hasConcept C197934379 @default.
• W4366332806 hasConcept C27415008 @default.
• W4366332806 hasConcept C2776412080 @default.
• W4366332806 hasConcept C2778375690 @default.
• W4366332806 hasConcept C2780057945 @default.
• W4366332806 hasConcept C50522688 @default.
• W4366332806 hasConcept C535046627 @default.
• W4366332806 hasConcept C71924100 @default.
• W4366332806 hasConcept C98274493 @default.
• W4366332806 hasConceptScore W4366332806C118552586 @default.
• W4366332806 hasConceptScore W4366332806C134362201 @default.
• W4366332806 hasConceptScore W4366332806C142724271 @default.
• W4366332806 hasConceptScore W4366332806C160735492 @default.
• W4366332806 hasConceptScore W4366332806C162324750 @default.
• W4366332806 hasConceptScore W4366332806C197934379 @default.
• W4366332806 hasConceptScore W4366332806C27415008 @default.
• W4366332806 hasConceptScore W4366332806C2776412080 @default.
• W4366332806 hasConceptScore W4366332806C2778375690 @default.
• W4366332806 hasConceptScore W4366332806C2780057945 @default.
• W4366332806 hasConceptScore W4366332806C50522688 @default.
• W4366332806 hasConceptScore W4366332806C535046627 @default.
• W4366332806 hasConceptScore W4366332806C71924100 @default.
• W4366332806 hasConceptScore W4366332806C98274493 @default.
• W4366332806 hasFunder F4320337415 @default.
• W4366332806 hasIssue "4" @default.
• W4366332806 hasLocation W43663328061 @default.
• W4366332806 hasLocation W43663328062 @default.
• W4366332806 hasLocation W43663328063 @default.
• W4366332806 hasOpenAccess W4366332806 @default.
• W4366332806 hasPrimaryLocation W43663328061 @default.
• W4366332806 hasRelatedWork W1689540773 @default.
• W4366332806 hasRelatedWork W2046851522 @default.
• W4366332806 hasRelatedWork W2093528092 @default.
• W4366332806 hasRelatedWork W2149026671 @default.
• W4366332806 hasRelatedWork W2165603261 @default.
• W4366332806 hasRelatedWork W2181333004 @default.
• W4366332806 hasRelatedWork W2333258705 @default.
• W4366332806 hasRelatedWork W2360077884 @default.
• W4366332806 hasRelatedWork W2884007892 @default.
• W4366332806 hasRelatedWork W4245069383 @default.
• W4366332806 hasVolume "13" @default.

• next